Antibodies News and Research

RSS

Study highlights role of specific protein in the mass production of antibodies

Antibodies play a fundamental role in medicine, and antibody-mediated immune response is the ultimate target in the quest for a vaccine to defeat the current pandemic.

16 Sep 2020

Researchers are testing the effectiveness of multiple treatments to prevent COVID-19

A study on the effectiveness of multiple treatments, including laboratory-made antibodies, at preventing mild COVID-19 from advancing to severe illness in the outpatient setting is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth).

16 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020

Patients with more severe SARS-CoV-2 infection exhibit larger antibody response

Researchers in the United States have found that individuals who develop more severe disease following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mount a larger antibody and memory B cell response during both acute infection and convalescence.

15 Sep 2020

Newly identified mechanism regulates the distensibility of the heart

A healthy heart beats 50 to 100 times a minute and pumps 8,000 litres of blood around our body every day. A precondition for this function is the elasticity of the cardiac walls, which dilate as blood flows in (diastole) and contract again as the blood flows out (systole).

15 Sep 2020

New antibody assay for COVID-19 promises sensitive mass-scale detection

A new paper by researchers at McMaster University and Hamilton Health Sciences, published on the preprint server medRxiv in September 2020, reports on the development of a serologic assay that is suitable for sensitive high-throughput antibody testing for COVID-19.

15 Sep 2020

Immunologists analyze types of immune response to predict an effective COVID-19 vaccine

Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

15 Sep 2020

Bio-Rad launches StarBright Violet 515 Dye for use in flow cytometry

Bio-Rad Laboratories, Inc., a global leader of life science research and clinical diagnostic products, today announced the launch of StarBright Violet 515 Dye, the first of a new range of unique fluorescent nanoparticles, for use in flow cytometry.

From Bio-Rad Laboratories 15 Sep 2020

3D printed nanoparticle biosensing platform detects SARS-CoV-2 antibodies within seconds

Pandemics caused by novel infectious agents like the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Zika, or Ebola virus seriously impact human health and lives while also overwhelming health care systems all over the world. Early detection and diagnosis allow isolation of the infected patients and contact tracing, which can mitigate the spread of the virus and save lives, especially when a significant number of the patients are asymptomatic.

14 Sep 2020

Central nervous system immune responses to COVID-19

A recent study published on the preprint server bioRxiv by scientists from Yale School of Medicine, University of California, Yale School of Public Health, Yale University, and Howard Hughes Medical Institute examined the impact of SARS-CoV-2 infection on the central nervous system.

14 Sep 2020

NIH and FDA examine serious side effect that surfaced in COVID vaccine trial

The Food and Drug Administration is weighing whether to follow British regulators in resuming a coronavirus vaccine trial that was halted when a participant suffered spinal cord damage, even as the National Institutes of Health has launched an investigation of the case.

14 Sep 2020

RUDN geneticist finds a bifidobacterial protein that can reduce inflammation in COVID-19

A geneticist from RUDN University studied the effect of Bifidobacterium (intestinal bacteria) on the inflammatory process and discovered that their surface protein is capable of stopping excessive or uncontrollable inflammation, like the one observed in COVID-19 patients.

14 Sep 2020

Oxford University and AstraZeneca resume COVID-19 vaccine trial

More than a hundred candidate vaccine trials against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19), are underway. About 35 are now undergoing clinical evaluation, and of these, nine are in the final phase of human trials, including the vaccine developed by Oxford University and the biopharmaceutical firm, AstraZeneca.

14 Sep 2020

Tiny antibody component shows high potency in SARS-CoV-2 animal models

University of Pittsburgh School of Medicine scientists have isolated the smallest biological molecule to date that completely and specifically neutralizes the SARS-CoV-2 virus, which is the cause of COVID-19.

14 Sep 2020

Toyonaka Municipal Hospital reports successful control of COVID-19

Researchers at Toyonaka Municipal Hospital in Japan have shown that the rate of subclinical infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among staff at the hospital is no higher than among the general population in the same area.

14 Sep 2020

Single-molecule imaging of SARS-CoV-2 spikes on virus particles

Using single-molecule FRET analysis, a team of researchers has revealed how the different conformations of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein are interconnected. Figuring out the different conformations in real-time and which conformations antibodies prefer may help design effective vaccines and drugs. The research is published on the preprint server bioRxiv*.

14 Sep 2020

Susceptibility of domestic pigs to SARS-CoV-2

A recent study published on the preprint server bioRxiv sought to determine the susceptibility of domestic swine to SARS-CoV-2. Domestic swine is one of the most highly produced agricultural species that has the potential to impact public health significantly.

14 Sep 2020

A map of SARS-CoV-2 escape mutations enables the development of therapeutic antibody cocktails

A recent tour-de-force study by the US researchers describes a comprehensive approach to completely map mutations to the SARS-CoV-2 receptor-binding domain (RBD) that escape antibody binding – enabling, in turn, rational design of antibody therapeutics and appraisal of the antigenic consequences of viral evolution. The results are currently available in a bioRxiv preprint paper.

13 Sep 2020

India's whole-virion inactivated SARS-CoV-2 vaccine shows promise

Researchers in India have conducted a preclinical study demonstrating the safety and efficacy of a new candidate vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

13 Sep 2020

Middle-aged adults may be in a perpetual state of H3N2 flu virus vulnerability

Penn Medicine researchers have found that middle-aged individuals -- those born in the late 1960s and the 1970s -- may be in a perpetual state of H3N2 influenza virus susceptibility because their antibodies bind to H3N2 viruses but fail to prevent infections, according to a new study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania.

12 Sep 2020